DA Davidson lowered the firm’s price target on Nordson (NDSN) to $285 from $295 and keeps a Buy rating on the shares after its Q4 results and below-consensus Q1 guidance. The firm has scaled back its organic growth assumptions across each of Nordson’s three reportable segments, the analyst tells investors in a research note. In MFS – Medical and Fluid Solutions – DA Davidson sees growth down low single digits as medical interventional demand has “yet to recover”, the firm adds.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NDSN:
- Nordson downgraded to Neutral from Outperform at Baird
- Nordson Corporation Reports Record Sales in 2024
- Adobe outlook disappoints, Kroger announces $7.5B buyback: Morning Buzz
- Closing Bell Movers: Adobe down over 8% on guidance shortfall
- Nordson Corporation Reports Record Fiscal 2024 Sales
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
